Compare Prudential PLC (PUK) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prudential PLC vs ResMed Inc. — how do they compare? Prudential PLC trades at $23.88 (market cap $28.84B), while ResMed Inc. trades at $229.66 (market cap $31.89B). The key difference: Prudential PLC and ResMed Inc. are close in size by market cap, and Prudential PLC pays the higher dividend (2.33%). Which is the better fit depends on your goals — on Pluang, investors hold Prudential PLC for 119 Days and ResMed Inc. for 51 Days on average.
| PUK | RMD | |
|---|---|---|
Market Cap | $28.84B | $31.89B |
Volume | 3,531,298 | 618,314 |
Sector | Financials | Health |
52-Week High | $33.61 | $277.88 |
52-Week Low | $23.54 | $182.82 |
Typical Hold Time | 119 Days | 51 Days |
Enterprise Value | $28.38B | $31.24B |
Dividend Yield | 2.33% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PUK trades at $23.54, down 4.31% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong revenue growth to $27.39B in 2025 and net income of $3.98B, with a net margin of 14.52%. Recent news highlights strategic moves including the sale of its Alexforbes stake and a rebranding of its wealth management unit. Analyst consensus is moderately bullish with 50% buy ratings.
The outlook is mixed: solid fundamentals and growth initiatives support upside, but technical weakness and earnings volatility pose risks. Investment opportunity lies in the attractive valuation (P/E 8.4) and strategic focus, countered by bearish momentum and competitive pressures in insurance markets.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
